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Heat shock protein 90 (Hsp90) has been demonstrated to protect oncogenic variants of signalling molecules from degradation and
may consequently serve as a therapeutic target for the treatment of oesophageal cancer for which adequate therapy is often lacking.
We studied the expression of Hsp90 in tumour tissues of human oesophageal cancer and the impact of Hsp90 inhibition on
oesophageal cancer cell lines using the drug 17-allylamino-17-demethoxygeldanamycin (17-AAG). Quantitative immunohistochemistry
was performed on formalin-fixed paraffin-embedded tissues from patients with oesophageal cancer. In squamous cell carcinoma, a
marked upregulation of Hsp90 could be noted in dysplastic epithelium and invasive cancer compared with normal epithelium. In
adenocarcinoma, Hsp90 was expressed in neoplastic epithelium and also in normal non-neoplastic glands weakly. The inhibition of
Hsp90 using 17-AAG led to a significant decrease in cell proliferation and viability in human oesophageal cancer cell lines. Using a
clonogenic cell survival assay, Hsp90 inhibition significantly sensitised the cells for g-photon irradiation. Heat shock protein 90 was
found to be critical for proper signalling induced by both epidermal growth factor and insulin-like growth factor-1, in which the
inhibition of signalling by 17-AAG correlated with the observed reduction in cell proliferation and viability. These results showed that
Hsp90 was selectively expressed in oesophageal cancer tissue compared with the corresponding normal tissue, and the inhibition of
Hsp90 resulted in decreased proliferation and viability as well as radiosensitisation of oesophageal cancer cells. Heat shock protein 90
represents a potential therapeutic target in the treatment of patients with oesophageal cancer, alone or in combination with
radiotherapy.
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Oesophageal cancer is histopathologically divided into adenocar-
cinomas and squamous cell carcinomas, but standard treatment is
similar, including surgery, irradiation and chemotherapy. Despite
advances in surgical techniques and treatment, the prognosis of
oesophageal cancer remains poor with very few long-term
survivors (Enzinger and Mayer, 2003).
Heat shock protein 90 (Hsp90) is an abundant protein that
functions as a chaperone, thus preventing protein aggregation and
helping denatured proteins to refold in an ATP-dependent fashion
(Panaretou et al, 1998; Meyer et al, 2003). 17-Allylamino-17-
demethoxygeldanamycin (17-AAG) is an inhibitor of Hsp90 that
binds to the nucleotide-binding site and thereby promotes the
release of the client proteins, which may then be degraded
(Schneider et al, 1996). In many cancer cells, Hsp90 functions to
protect and stabilise overexpressed or mutated signal transduction
proteins, thus indirectly promoting cell growth and survival (Neckers
and Ivy, 2003). A role for Hsp90 in the regulation of apoptosis has
also been suggested, acting both in an antiapoptotic and pro-
apoptotic manner (Pandey et al, 2000; Nieto-Miguel et al, 2007).
Hanahan and Weinberg (2000) have suggested that the
transformation of a normal cell into a cancer cell requires six
essential alterations in cell physiology that collectively dictate
malignant growth: self-sufficiency in growth signals, insensitivity
to growth-inhibitory signals, evasion of apoptosis, limitless
replicative potential, sustained angiogenesis and tissue invasion
and metastasis (Hanahan and Weinberg, 2000). In a review by Xu
and Neckers (2007), it is pointed out that because many Hsp90
client proteins play significant roles in each of these alterations,
the therapeutic potential of targeting Hsp90 may be best
appreciated by considering the possibility of simultaneously
targeting the six hallmarks of a cancer cell.
In this report, we investigate the expression of Hsp90 in human
oesophageal cancer and the importance of Hsp90 for oesophageal
cancer cell proliferation and sensitivity towards g-photon
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sradiation. Our results show that Hsp90 is abundantly expressed in
human tumours of oesophageal cancer as well as in human
oesophageal cancer cell lines. 17-Allylamino-17-demethoxygeldana-
mycin effectively inhibits cell proliferation of oesophageal carcinoma
cell lines, indicating the presence of mutated or overexpressed
signalling proteins that are protected from degradation by Hsp90. In
addition, Hsp90 inhibition increases the sensitivity towards g-photon
radiation. The effect of 17-AAG on proliferation and radiosensitivity
is correlated with the ability of 17-AAG to downregulate growth
factor-mediated signal transduction.
MATERIALS AND METHODS
Cell culture, antibodies and reagents
Kyse30, -70, -140, -150, -180, -410, -450, -510 and -520 cell lines
derived from oesophageal squamous cell carcinoma were
purchased from Deutsche Sammlung von Mikroorganismen und
Zellkulturen (Braunschweig, Germany). Cells were cultured in
RPMI-1640 medium (Sigma, St Louis, MO, USA) supplemented
with 10% foetal bovine serum, 50Uml
 1 penicillin, 100mgml
 1
streptomycin and 2mML -glutamine in a 371C incubator with
humidified atmosphere and 5% CO2. Antibodies used were
anti-epidermal growth factor receptor (EGFR), anti-insulin-like
growth factor-1 (IGF)-1Rb and anti-Akt1/2 rabbit polyclonal
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
anti-Hsp90 mouse monoclonal antibodies (Biosite, San Diego, CA,
USA), anti-phosphotyrosine mouse monoclonal antibodies PY99
(Santa Cruz), phosphospecific anti-Erk and phosphospecific anti-
Akt antibodies (Cell Signalling Technology, Beverly, MA, USA) and
anti-b-actin mouse monoclonal antibodies (Sigma) and horse-
radish peroxidase (HRP)-conjugated anti-mouse IgG or anti-rabbit
IgG secondary antibodies (Amersham Biosciences, Piscataway, NJ,
USA). Anti-Erk2 rabbit serum was from the Ludwig Institute,
Uppsala, Sweden. Gefitinib was from Biaffin GmbH & Co. KG
(Kassel, Germany), 17-AAG from AG Scientific Inc. (San Diego,
CA, USA), EGF from Chemicon International Inc. (Temecula, CA,
USA) and IGF-1 from R&D Systems Inc. (Minneapolis, MN, USA).
Patients
All patients with oesophageal carcinoma admitted to the Depart-
ment of Oncology, University Hospital, Uppsala, Sweden, during
1990–2000 were included. The study was reviewed and approved
by the research ethics committee, Uppsala University, Uppsala,
Sweden. A total of 126 patients were included; however, only
formalin-fixed paraffin-embedded tissues from 81 patients could
be retrieved and thereby included in the study. The clinical
parameter investigated was survival.
Immunohistochemical analysis
Heat shock protein 90 immunohistochemical (IHC) staining was
performed in 81 archival paraffin-embedded tumour samples. The
immunostaining was performed according to the method pub-
lished by Dreilich et al (2006). Samples with a known expression of
Hsp90 (HeLa cells) were used as positive control. Sections were
incubated with the primary antibody (Hsp90 Ab-2 (JPB24), Santa
Cruz) and an automated immunohistochemical system from
Ventana (Benchmark; Ventana Medical Systems, Tuscon, AZ,
USA) was employed according to the manufacturer’s recommen-
dations. Immunostained tissues were annotated by an experienced
gastrointestinal pathologist according to the criteria used in the
Swedish human protein atlas program (http://www.proteinatlas.
org/annotdesc.php). The extent of positive tumour cells was scored
using a three-grade scale: (1) o25% positive tumour cells,
(2) 25–75% positive cells and (3) 475% of tumour cells staining
positively. The intensity of immunoreactivity in tumour cells was
evaluated using a four-grade scale: faint (1), weak (2), moderate (3)
and strong (4). The extent and intensity scores were used as a basis
for grading immunoreactivity in oesophageal cancer cells. In
addition, the subcellular localisation was evaluated: membranous,
cytoplasmic or nuclear positivity.
Statistical analysis
Heat shock protein 90 was evaluated as a dichotomous variable.
The expression of Hsp90 was according to above. Survival was
estimated using the Kaplan–Meier product limit method, with
univariate analysis being performed using a log-rank test. Cox
regression analysis was performed to investigate if certain
continuous factors had a significant effect on survival. Throughout
the study, a 5% significance level was used.
Proliferation assay
Duplicates of 50000 cells suspended in complete medium were
seeded into the wells of 12-well plates (Fisher Scientific, Pittsburgh,
PA, USA). After the cells were attached, 17-AAG or gefitinib was
added to each well at the designated concentration. The concentra-
tion of DMSO in the control and treatment wells was 0.1%. Cells were
trypsinised and counted in a cell counter (Beckman Coulter,
Fullerton, CA, USA) after the indicated periods of time. The number
of cells in untreated control wells was defined as 100%.
Apoptosis assay
Kyse70 and Kyse450 cells were plated, returned to the incubator
for 24h and then treated with 17-AAG or DMSO for another 24h
and exposed to irradiation. After that, the drug was removed and
fresh medium added, and the cells were incubated for another 48h.
Both floating and attached cells were collected by centrifugation.
Apoptosis analysis was performed according to the manufacturer’s
instructions (Annexin V-FITC Apoptosis detection kit; R&D
Systems Inc.). Results for early and late apoptosis were added
together as total amount of apoptosis (Bisht et al, 2003; Martins
et al, 2008) (I add the reference, but the format is stange).
Irradiation and clonogenic survival assay
Cells were seeded into T-25 flasks at a density of 2 10
5 per flask
and allowed to grow for 24h in a humidified atmosphere with 5%
CO2 in a 371C incubator. After attaining sufficient growth, the
designated concentration of 17-AAG or gefitinib was added to
the growth media and the cells were incubated for 24h. Thereafter,
the cells were irradiated with 2, 4, 6 or 8Gy g-photons from a
137Cs
source (1.3Gymin
 1; Gammacell 40 Exactor; MDS Nordion,
Ottawa, ON, Canada). Following irradiation, cells were trypsinised
and plated onto 10-cm tissue culture dishes at various cell densities
for clonogenic cell survival. Cells were incubated for 10–11 days,
fixed with ethanol and stained by haematoxylin. Clonogenic cells
were defined as those able to form a colony of atleast 50 cells.
Radiosensitivity was quantified as area under curve (AUC), and the
effect of 17-AAG on radiosensitivity is expressed as sensitiser
enhancement ratio (SER), defined as AUCcontrol/AUCtreated.
Immunoprecipitation and western blot analysis
For ligand stimulation and 17-AAG treatment, subconfluent
Kyse70 and Kyse450 cells were treated with 0.5, 1 and 1.5mM 17-
AAG for 24 and 48h as indicated in starvation medium containing
0.1% foetal bovine serum at 371C. Next, the cells were stimulated
with 100ngml
 1 EGF or IGF-1 for 5min and washed with cold
phosphate-buffered saline before lysis. Cell lysates were prepared
according to Lennartsson et al (2006). Briefly, total protein
concentration was determined using the BCA Protein Assay Kit
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s(Pierce, Rockford, IL, USA). Total cell lysates were submitted to
SDS–polyacrylamide gel electrophoresis. For immunoprecipita-
tion, antibodies against Hsp90 were added to each lysate at a
concentration of 1mgml
 1. Protein G beads were added to collect
immunocomplexes. After washing beads, samples were boiled in
reducing sample buffer and subjected to SDS–polyacrylamide gel
electrophoresis. Separated proteins were electrotransferred to
polyvinylidene fluoride membranes (Millipore, Billerica, MA,
USA). Membranes were blocked using 5% BSA, incubated with
primary antibody overnight at 41C and then incubated with HRP-
conjugated anti-mouse or anti-rabbit IgG antibodies (both from
Amersham Biosciences). Proteins were visualised using an ECL
western blotting detection system from Roche Applied Science on
a cooled charge-coupled device camera (Fuji, Minami-Ashigata,
Japan). Before reprobing, the membranes were stripped with 0.4 M
NaOH for 10min at room temperature, blocked and incubated
with the corresponding antibody.
RESULTS
Hsp90 expression in tumours and cell lines of human
oesophageal cancer
To evaluate Hsp90 as a potential target for therapy in oesophageal
cancer, the protein expression of Hsp90 was investigated in
tumours from 81 oesophageal cancer patients, 53 squamous cell
carcinomas and 28 adenocarcinomas, using IHC staining. From
the original 85 patients included, four patients had to be excluded
due to uncertain histology. For both squamous cell carcinomas
and adenocarcinomas, the majority of tumours were found to
express Hsp90 at weak-to-moderate intensity levels (44 and 56%,
respectively) (Figure 1A and B, and Table 1), but squamous cell
carcinomas displayed a higher fraction of moderately expressing
tumours (23%) compared with adenocarcinomas (4%). Further-
more, adenocarcinomas showed a higher extent of weak staining
(40%) compared with squamous cell carcinomas (30%). There was
also less difference in staining intensity between tumour and
normal tissue in adenocarcinomas compared with squamous
carcinomas. Normal oesophageal squamous epithelium had only
a faint Hsp90 expression of the basal cell layer (Figure 1D). For
both squamous and glandular epithelium, a low-to-moderate
staining was observed in dysplastic epithelium (Figure 1C).
Preferentially, cytoplasmic staining was observed, representing
70% of the tumours (57 out of 81). Nuclear staining was observed
in 2.5% of the tumours (2 out of 81), whereas 13.6% (11 out of 81)
displayed both cytoplasmic and nuclear localisation (Figure 1A).
The importance of these findings remains to be elucidated, but the
dominating cytoplasmic Hsp90 staining is consistent with a
function for Hsp90 in stabilising signal transduction molecules
in this cellular compartment.
Analysing the protein expression of Hsp90 in human oesopha-
geal cancer cell lines, we found a strong expression in all nine cell
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Figure 1 Hsp90 is expressed in tumours and cell lines of human oesophageal cancer. Protein expression of Hsp90 was evaluated in tumours from 81
oesophageal cancer patients using an immunohistochemical staining procedure. Representative stainings of tumour tissues are shown in (A) (squamous cell
carcinoma), (B) (adenocarcinoma) and (C) (dysplasia), whereas staining of normal oesophageal epithelium is demonstrated in (D). A predominant
cytoplasmic staining was observed in the oesophageal tumours, as indicated by an arrow in the box of figure (A). Scale bar¼50mm( A) or 100mm( B–D).
(E) Hsp90 was immunoprecipitated (Ip) and the membrane was subjected to immunoblotting (Ib) with antibodies against phosphotyrosine (upper panel) or
Hsp90 (lower panel). The experiment was repeated atleast three times, a representative result is shown.
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slines analysed (Figure 1E). This is consistent with earlier reports
demonstrating abundant Hsp90 expression in various tumour cells
(Ferrarini et al, 1992; Liu et al, 1999; Pick et al, 2007). We selected
Kyse70 and -450 for further investigations.
Hsp90 as a prognostic factor in oesophageal cancer
The expression of Hsp90 in oesophageal tumours was evaluated in
relation to survival using the Kaplan–Meier product limit method,
with univariate analysis being performed using a log-rank test.
Both intensity and the extent of staining were evaluated. No
significant correlation to survival was observed, neither for
intensity (P¼0.68) (Figure 2A) nor for extent (P¼0.38)
(Figure 2B). Type of histology, squamous cell carcinoma or
adenocarcinoma, did not make any difference (P¼0.50 and
P¼0.93 for intensity, respectively; data not shown). Detailed
characteristics of patients and IHC stainings are shown in Table 1.
Hsp90 blockade by 17-AAG inhibits cell proliferation and
survival
Considering the fact that Hsp90 was expressed in all oesophageal
tumours analysed, we investigated the role of Hsp90 in cell
proliferation and survival by performing specific inhibition using
17-AAG. Both Kyse70 and Kyse450 cell lines displayed a dose- and
time-dependent reduction in cell proliferation (Figure 3, upper
panels). A maximal reduction of proliferation was achieved after
treatment with 500nM 17-AAG for 48h, where Kyse70 and Kyse450
showed 80 and 84% inhibition, respectively.
Epidermal growth factor receptor is often abundantly expressed
in oesophageal cancer (Ozawa et al, 1987; Mukaida et al, 1991) and
therefore we tested the ability of gefitinib to inhibit cell
proliferation. At 48h of treatment with 3mM gefitinib, there was
a 31% reduction of proliferation for Kyse70 and 49% for Kyse450
(Figure 3, lower panels). The gefitinib concentrations chosen
correspond to the plasma concentrations of gefitinib in treated
patients (Sharma et al, 2007). Using 3mM gefitinib for 48h, a
significantly lower inhibition of proliferation was seen compared
with 500nM 17-AAG for 48h (Po0.05 for both Kyse70 and
Kyse450 cells).
Table 1 Characteristics of patients and immunohistochemical stainings
Staining intensity Extent of staining
No. of patients Survival (days) 1 2 3 4 1 2 3
Gender
Male 59 433 18 (30%) 27 (46%) 13 (22%) 1 (2%) 2 (3%) 16 (27%) 41 (69%)
Female 26 731 10 (42%) 12 (50%) 1 (4%) 1 (4%) 1 (4%) 7 (27%) 18 (69%)
Histology
Squamous cell 59 556 17 (30%) 25 (44%) 13 (23%) 2 (4%) 1 (2%) 14 (24%) 44 (75%)
Adenocarcinoma 25 452 10 (40%) 14 (56%) 1 (4%) 0 ( ) 2 (8%) 8 (32%) 15 (60%)
Other 1 — — — — — — — —
Stage
Localised 27 251 11 (41%) 10 (37%) 6 (22%) 0 (0%) 1 (4%) 8 (30%) 18 (66%)
Advanced 58 651 17 (30%) 29 (52%) 8 (14%) 2 (4%) 2 (3%) 15 (26%) 41 (71%)
Localisation of tumour
Upper 9 686 5 (63%) 2 (25%) 1 (13%) 0 (0%) 1 (11%) 4 (44%) 4 (44%)
Middle 26 594 9 (36%) 15 (60%) 1 (4%) 0 (0%) 1 (4%) 6 (23%) 19 (73%)
Lower 42 372 11 (26%) 19 (45%) 10 (24%) 2 (5%) 1 (2%) 11 (26%) 30 (71%)
Survival in all patients based on intensity of staining for HSP 90 (P=0.68)
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Figure 2 Hsp90 is not a prognostic factor in oesophageal cancer. The
expression of Hsp90 in oesophageal tumours was evaluated in relation to
survival using the Kaplan–Meier product limit method, with univariate
analysis being performed using a log-rank test. Both (A) intensity and (B)
the extent of staining are shown.
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sThe effect of 17-AAG on apoptosis induction was studied in the
Kyse cell lines. As depicted in Figure 4A and B, treatment with
17-AAG alone resulted in significantly (Po0.05) increased rates of
apoptosis, with 18% apoptosis for Kyse70 and 13% for Kyse450
compared with control. These results showed that 17-AAG can
induce apoptotic cell death in oesophageal cancer cells.
Hsp90 inhibition can radiosensitise oesophageal cells
Earlier studies have indicated that Hsp90 inhibition may radio-
sensitise tumour cells (Camphausen and Tofilon, 2007). To address
the same issue in oesophageal cancer cells, we performed
clonogenic cell survival assays to measure in vitro cell killing as
a function of radiation dose. Kyse70 and Kyse450 cells were
irradiated with 2, 4, 6 or 8Gy g-photons in the presence or absence
of 17-AAG and cell survival was studied. Exposure to 17-AAG
alone resulted in 51% cell survival for Kyse70 and 61% cell survival
for Kyse450 (Figure 5A). Cell survival after 2, 4, 6 and 8Gy
irradiation for Kyse70 was 56, 24, 6.9 and 1.2%, respectively.
Theoretically, the expected additive cell survival of Kyse70 after
exposure to drug and g-photons (0.51 survivalg) should be
approximately 28, 12, 3.5 and 0.6%. However, the achieved cell
survival after combination was less; 21, 7.5, 1.5 and 0.2% for 2, 4, 6
and 8Gy, respectively (Figure 5A). For Kyse450 this effect was even
more apparent. At 2, 4, 6 and 8Gy, the expected additive survival
should be 46, 29, 13 and 3.7%, whereas the achieved survival was
18, 6.2, 2.2 and 0.7% (Figure 5A). Figure 5B (upper panels) showed
the survival curves of Kyse70 and Kyse450 after g-photon
irradiation or g-photon combined with 17-AAG treatment. As
irradiated and 17-AAG-treated cells were normalised to 17-AAG-
treated controls, the figure only reflects the radiosensitising effect.
We observed that 17-AAG sensitised the radioresistant Kyse450
cells more than the radiosensitive Kyse70 cells, and the obtained
SERs were 2.1 and 1.5, respectively. Importantly, gefitinib
treatment was not able to radiosensitise either Kyse70 or Kyse450
cells (Figure 5B, lower panels).
Apoptosis is a mode of cell death in response to radiation. As
depicted in Figure 4A and B, radiation (6Gy) significantly
increased apoptosis for both cell lines compared with control
(Po0.05). Apoptosis rate for Kyse70 cells was approximately 12%
and for Kyse450 cells was approximately 18% at 6Gy. When
17-AAG was combined with radiation, the apoptosis rate increased
to 32% for Kyse70 and 24% for Kyse450, significantly higher rates
compared with radiation or 17-AAG treatment alone (Po0.05).
17-AAG inhibits pro-survival signalling pathways
Epidermal growth factor receptor is often overexpressed in
patients with oesophageal cancer, suggesting an important role
for it in the development of this disease (Sarbia et al, 2007; Wang
et al, 2007; Wei et al, 2007). All Kyse cell lines were found to
express EGFRs, whereas HER2 was expressed only in Kyse410
(data not shown). Furthermore, we observed an interaction
between the EGFR and Hsp90 in co-immunoprecipitation experi-
ments (Figure 6A). In addition, we could detect tyrosine
phosphorylation of Hsp90 in all of the cell lines (Figure 1E, upper
panel). Notably, the level of Hsp90 phosphorylation was not
sensitive to either 17-AAG or gefitinib treatment (data not shown).
Epidermal growth factor receptor was downregulated by 17-AAG
treatment in a dose- and time-dependent manner in both Kyse70
and Kyse450 cell lines (Figure 6B). Moreover, we found that the
EGF-induced activation of the downstream signalling proteins Erk
and Akt was also inhibited by 17-AAG (Figure 6C). Interestingly,
the level of Akt protein was sensitive to 17-AAG treatment,
whereas the inhibition of Erk signalling was not due to changes in
total protein levels. As Hsp90 is known to have many different
client proteins, we wanted to investigate whether other pro-
survival signalling pathways were affected in a similar way by the
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Figure 3 17-AAG inhibits proliferation of oesophageal cancer cell lines. Kyse70 (left) and Kyse450 (right) cells were treated with the indicated
concentrations of 17-AAG (upper panels) or gefitinib (lower panels) for the indicated periods of time, and cells were then counted. Relative number of cells
as % of control was calculated and shown. Each data point had at least three repeats.
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sinhibition of Hsp90. The IGF-1 signalling cascade is a well-
established and ubiquitously expressed pro-survival pathway, and
the IGF-1 receptor has been proposed to confer survival signals to
a wide range of tumour cells (Liu et al, 2002; Stromberg et al,
2006). As the IGF-1 receptor is also expressed in Kyse70 and
Kyse450 cells, we wanted to investigate whether 17-AAG could also
downregulate this survival pathway. As can be seen in Figure 6B,
we found that 17-AAG efficiently downregulated the IGF-1
receptor. In concurrence, IGF-1-induced Erk and Akt activation
was also potently inhibited by 17-AAG treatment (Figure 6D).
DISCUSSION
Several reports have indicated the important role of Hsp90 in
carcinogenesis (Isaacs et al, 2003; Citri et al, 2004; Zhang and
Burrows, 2004). However, studies in oesophageal cancer are sparse
and to elucidate this issue further, this study sought to evaluate the
importance of Hsp90 as the primary target for novel therapy using
17-AAG in oesophageal cancer.
Heat shock protein 90 was found to be expressed in all
investigated oesophageal tumours (81 patients), whereas normal
oesophageal epithelium expressed no or very low levels of the
protein. The selective expression in this tumour showed promise
for further evaluation of Hsp90 as a target for therapy in
oesophageal cancer. The observed data are in contrast to the
study by Faried et al (2004), who demonstrated an expression of
Hsp90 in only 50% of the tumours (123 cases). The reason for the
observed differences is not clear. All cases in the study by Faried
et al (2004) were squamous cell carcinomas, whereas our study
included both squamous cell carcinomas and adenocarcinomas,
however, the squamous cancers dominating (65%) and all
demonstrating a clear expression of Hsp90. These contradictory
results might be explained by differences in stages of disease,
treatment modalities as well as different populations, which may
have different expressions of oncogenic proteins as seen for HER2
in oesophageal cancer (Lam et al, 1998; Dreilich et al, 2006).
Furthermore, a relatively higher expression of Hsp90 was found in
squamous cell carcinomas compared with adenocarcinomas, a
finding that has never been reported before. Both squamous and
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Figure 4 Effects of 17-AAG on apoptosis of oesophageal cancer. Subconfluent Kyse70 and Kyse450 cells were treated with 1.5mM 17-AAG, exposed to
irradiation (6Gy), or treated with 17-AAG before exposure to irradiation. Cells were harvested at 48h after exposure to irradiation and apoptosis was
analysed by flow cytometry using Annexin-V/PI detection. Results of early and late apoptosis were added together to calculate the total amount of apoptosis.
(A) Graphical representation of apoptosis for all treatments of Kyse70 and Kyse450 cells. Irradiation, 17-AAG and the combination could induce apoptosis
for both cell lines. Combination of irradiation and 17-AAG induced a higher degree of apoptosis in Kyse70 compared with Kyse450 cells. (B) Bar graph of all
conditions. Irradiation combined with 17-AAG resulted in an additional increase of apoptosis in both cell lines. Statistical significance was established by t-test.
*Po0.05; this treatment showed a difference compared with other treatments and control.
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sglandular epithelium displayed a low-to-moderate staining in
dysplastic epithelium. A similar finding was reported by Ito et al
(1998), who demonstrated the expression of Hsp90 already in
dysplastic lesions of squamous epithelium of the tongue. This is
consistent with the notion that early in tumorigenesis, the
incipient tumour experiences ‘oncogenic stress’, which evokes a
DNA damage response network that delays or prevents cancer
(Bartkova et al, 2005). This ‘oncogenic stress’ results in the
inducible expression of heat shock proteins that assist in the
recovery from stress either by repairing damaged proteins (protein
refolding) or by degrading them, thus restoring protein homo-
eostasis and promoting cell survival (Jolly and Morimoto, 2000). In
Barrett’s oesophagus, a reduced expression of heat shock proteins
in metaplasia followed by a significant increase in expression
during progression was shown (Doak et al, 2004; Ostrowski et al,
2007). Thus, the expression of heat shock proteins, including
Hsp90, presents potential as a prognostic tool to predict the
aggressiveness of oesophageal carcinomas.
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Figure 5 17-AAG radiosensitises oesophageal cancer cell lines. Clonogenic cell survival of Kyse70 and Kyse450 cells following 17-AAG treatment
(1.5mM for 24h) and/or g-photon irradiation (2, 4, 6 or 8Gy). (A) Shows survival fraction as a function of 17-AAG, g-dose and their combination. (B) Shows
survival plots as a function of g-dose in the absence or presence of 17-AAG or gefitinib at the indicated concentrations. The sensitiser enhancement ratio
(SER) for 17-AAG was calculated to be 1.5 and 2.1 for Kyse70 and Kyse450, respectively. Survival data were fitted to a linear quadratic curve fit,
S¼exp( aD bD
2) where D is the dose in Gy and a and b are fitting parameters, nX6, error bars represent standard deviation. All 17-AAG treatment
groups had P-values o 0.05.
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sA preferential cytoplasmic localisation of Hsp90 was found in
the tumours (70%), whereas nuclear staining was detected in only
2.5% of the cases. These results are contradictory to the data
reported earlier in malignant tumours, in which Burkitt et al
(2007) observed nuclear localisation in 40% (10/25) of prostatic
adenocarcinomas, but in none of the non-malignant specimens. In
pancreatic malignancy, 14 out of 15 (93%) had nuclear staining,
whereas none had nuclear staining in non-malignant tissue.
A change in localisation of Hsp90 in tumours would be predicted
to change the pattern of bound Hsp90 clients and may contribute
to the specificity of 17-AAG for tumour cells. Furthermore, a study
in human breast cancer demonstrated a positive correlation
between strong nuclear staining for Hsp90 and high MHC class I
expression, leading to the hypothesis that tumour cells with a high
MHC class I expression may escape apoptosis by a mechanism
involving increased nuclear Hsp90 (Gebhard et al, 1999). The
importance of predominant cytoplasmic staining in oesophageal
cancer remains to be determined, but may reflect an increased
binding of cytoplasmic Hsp90 client proteins.
In this study, we observed Hsp90 expression in all oesophageal
cancer cell lines investigated. Moreover, we detected tyrosine
phosphorylation of Hsp90, which recently has been connected to
Hsp90 functions in vascular endothelial growth factor receptor-2
signalling (Duval et al, 2007). However, the functional consequence
of Hsp90 tyrosine phosphorylation in our model system is not
understood and warrants further investigation. Studies on breast
cancer patients have shown that a high Hsp90 expression was
found to be associated with decreased survival in breast
cancer (Pick et al, 2007). In a study by Lebret et al (2007), the
authors found that the loss of expression of Hsp90 was
correlated with a worse clinical outcome in patients with bladder
carcinoma. Regarding oesophageal cancer, Faried et al (2004)
studied the prognostic importance of Hsp60 and Hsp90 in
oesophageal cancer patients and found no correlation with
prognosis for Hsp90, whereas Hsp60 expression correlated with
favourable prognosis. This is consistent with the results of this
study, in which no significant correlation was found between
Hsp90 expression and survival, neither for squamous cell
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Figure 6 Hsp90 interacts with the EGF receptor and 17-AAG treatment downregulates EGF and IGF-1 receptor signalling. Cells (Kyse70 and Kyse450)
were grown to confluence and then lysed. (A) Hsp90 was immunoprecipitated (Ip) and the membrane was subjected to immunoblotting (Ib) with
antibodies against EGF receptor. (B) Kyse70 and Kyse450 cells were treated with 17-AAG at increasing concentrations for 24 or 48h. Total cell lysate (TCL)
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scarcinoma nor for adenocarcinoma, as all tumours analysed
displayed robust Hsp90 staining regardless of the disease outcome.
In contrast, normal tissue displayed no or weak staining, indicating
that Hsp90 may represent a tumour-selective therapeutic target.
The inhibition of Hsp90 using 17-AAG in two oesophageal cell
lines (Kyse70 and Kyse450) resulted in an inhibition of cell
proliferation in a dose- and time-dependent manner. This is
consistent with studies on other tumour types, for example,
cervical carcinoma, lymphoma and thyroid cancer, in which 17-
AAG treatment showed antiproliferative activity (Park et al, 2003;
Schumacher et al, 2007; Schwock et al, 2008). Furthermore, we
found that treatment with 17-AAG sensitises oesophageal cancer
cells to g-photon radiation. A further observation was that SER was
larger for Kyse450 than for Kyse70, 2.1 and 1.5, respectively. It
should be noted that Kyse450 is more radioresistant than Kyse70,
and our results are thus consistent with reports that 17-AAG has a
better sensitisation effect on radioresistant cell lines (Russell et al,
2003; Machida et al, 2005). Inhibition of the EGFR, which is highly
expressed in these cell lines and frequently expressed at high levels
in oesophageal tumours, did not influence the radiosensitivity,
although we could observe an effective inhibition of EGFR
signalling after gefitinib treatment (data not shown).
The inhibition of Hsp90 has been shown to impair EGF-
mediated signalling in gastric cancer cells (Lang et al, 2007a).
Inhibitory effects on other growth factor signals have also been
implicated, for example, IGF-1R (Lang et al, 2007b) and Kit (Bauer
et al, 2006). We found that the reduced proliferation and
radiosensitising effects of Hsp90 inhibition in oesophageal cancer
cell lines correlated with a decrease in growth factor-induced
signalling. In Kyse410 and Kyse520 cells we noticed that the co-
immunoprecipitating EGFR appears as a band of higher molecular
weight than expected (Figure 6A). Elucidation of the reason for
this apparent increase in molecular weight warrants further
investigations, but possible explanations include mutations
(insertion) or a high level of post-translational modification.
When we analysed the effect of 17-AAG on the receptors for EGF
and IGF-1 we found that 17-AAG treatment downregulated both
the receptors in a time- and dose-dependent manner. In addition,
the downstream signalling molecules Akt and Erk were inhibited.
Given that the reduced Erk phosphorylation was not due to
decreased protein levels it is likely a secondary effect caused by
receptor downregulation in response to 17-AAG. In contrast,
reduced levels of phosphorylated Akt were reflected in lower levels
of total Akt protein; thus, activated Akt may require Hsp90 activity
to avoid degradation. However, the inactivation or downregulation
of upstream Akt regulators is also likely to contribute to the
reduced Akt phosphorylation in the presence of 17-AAG
treatment.
The radiosensitising effect of 17-AAG may potentially be due to
its ability to affect a range of signalling components simulta-
neously, for example both EGF and IGF-1 signalling networks as
described above. Moreover, we observed that Hsp90 inhibition
blocks serum-induced tyrosine phosphorylation of several proteins
of unknown identity (data not shown). The resulting combinatorial
effect may be of significance as more selective compounds such as
gefitinib, although effectively preventing EGF signalling, were not
able to radiosensitise the cells in our study.
In conclusion, our data suggest that Hsp90 represents a novel
target in oesophageal cancer therapy both in a single-drug and a
radiosensitising setting, conceivably by its ability to impede with a
large spectrum of cellular components controlling proliferative
and antiapoptotic signalling pathways.
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